Promising results have been reported in TCF3-PBX1 B-ALL [127] and in hypodiploid B-ALL [6,11], suggesting that Bcl2 inhibition could be a encouraging strategy also for the treatment of these B-ALL subtypes. Here, TCF3 is linked to acute lymphoblastic leukemia.